AbbVie has released a new set of eye drops approved by the US Food and Drug Administration, aiming to help people with blurry vision. The focus of the recent drops is to help the elderly correct the blurry vision which they experience and suffer from, primarily as the eyes are also known to deteriorate as time goes by.
AbbVie Blurry Vision Eye Drops Gets FDA Approval
AbbVie has released a report regarding its recent approval from the FDA for the use of its drug called "VUITY," an eye drop solution that helps fix the problem of blurry vision. The drops are made explicitly for people with old age that experiences this problem more often, mainly as it occurs to their age group.
"This significant innovation in age-related eye health reflects our commitment to advance vision care and expands our leading portfolio of treatments for eye care providers and their patients." Jag Dosanjh said.
The initial control group used in this study consists of 40 to 55-year-old individuals that suffer from blurry vision, something called Presbyopia.
Read Also: Moderna Research Shows Difficulty in mRNA Flu Vaccine Creation, 'Not a Silver Bullet'
What is Blurry Vision and How to Fix it?
The recent FDA approval of VIUTY focuses on its means to fix the problem experienced by the elderly called "presbyopia," or blurry near vision. It was said that reading things even near a person could be blurry, and it is often attributed to the deterioration of the eyes.
However, the condition is known to be something that a lot has suffered from, which could still be treated with the likes of the drops. The VIUTY drops are to be administered as needed by the patient and as prescribed by their physicians.
Health Advancements Now
AbbVie is one of the top regarded research and pharmaceutical companies in the world now, and it helps in the many focuses it has on different medicines. One of which is a rheumatoid arthritis drug that the company intends to focus on soon release. AbbVie has been a top-regarded health company and is popular among ventures.
It has been approached by Google and its health startup company, Calico, with a massive $1.5 billion investment in the research and development of the two joint bodies. The research venture would focus on the many supposed experiments of the company, tapping into tech and development into health and human development.
AbbVie's recent approval with the FDA shows that it has a lot of ventures left to give the public, especially with addressing health issues that include the undeniable changes as time goes by. Ageism is a normal process that a person would experience in their life, but that does not mean that their specific problems should be set aside.
Related Article: HarmonyOS Potential New Feature Could Help Monitor Blood Pressure
This article is owned by Tech Times
Written by Isaiah Richard
